Shilpa Medicare Ltd (Shilpa Medicare) develops, manufactures and markets generic pharmaceutical products. It conducts the production and export of active pharmaceutical ingredients APIs, formulations, new drug delivery systems, peptides, specialty chemicals and intermediates. The company offers oncology and non-onclogy APIs such as anastrozole, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide monohydrate, dasatinib, decitabine, erlotinib HCL, fingolimod hydrochloride, gemcitabine hcl, imatinib mesylate, irinotecan HCI trihydrate, lenalidomide, letrozole, melphalan HCL, nifedipine, oxaliplatin, pemetrexed disodium hemipentahydrate, sunitinib malate, temozolomide, thalidomide, and zoledronic acid.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Shilpa Medicare's research and development endeavors are meticulously aligned with intellectual property standards. The intellectual property management & legal affairs cell adeptly synchronizes and supervises the management of its product pipeline and patent portfolio. The company has R&D centers at Raichur, Bangalore, and Hubli. The company is dedicated to perpetually enhancing business productivity. It has substantiated this dedication by submitting nearly 250 patent applications across various countries, including India, Australia, Canada, the US, Europe, Japan, and New Zealand. This reaffirms its established track record of innovation and patent submissions.